Jeffrey Bluestone, Ph.D.

Jeffrey Bluestone, Ph.D.

President and CEO, Parker Institute for Cancer Immunotherapy
University of California, San Francisco, A. W. and Mary Margaret Clausen Distinguished Professor

Jeffrey is Distinguished Professor at the University of California, San Francisco, and the President and CEO of the Parker Institute for Cancer Immunotherapy. A leading immunologist in the field of T-cell activation, co-stimulation and immune tolerance research, he has led the development of multiple pro-tolerogenic immunotherapies, including CTLA4Ig, the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation, a novel anti-human CD3 antibody being developed to treat type 1 diabetes, and the first CTLA-4 antagonist drugs approved for the treatment of metastatic melanoma.